Associated Papers
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.
Hulse M et al.
Cancer Research, 2026
ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma.
Seidel P et al.
Jci Insight, 2022
36413415 (PubMed )
Supplement: jciinsight-7-156087-s060.xlsx › A498
Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.
Fernando TM et al.
Nature Communications, 2020
33144586 (PubMed )
Supplement: 41467_2020_19402_MOESM6_ESM.xlsx › Sheet1
Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers.
Schick S et al.
Nature Genetics, 2019
31427792 (PubMed )
Supplement: EMS83287-supplement-Supplementary_Table_1.xlsx › cell_lines
Select a paper to view details